The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Procaps Group
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
Resource Optimization Software Business Area of Net Insight
Advising Net Insight AB, a global leader in media networks, on the divestment of its resource optimization software business area, doing business as “ScheduALL” to Xytech Systems Corporation
WEX Inc. - Brazilian Operations/Subsidiary
Advised WEX Inc., a leading fleet and B2B payments company, on the divestiture of its Brazilian subsidiary to Vila Rica Capital.
VX Fiber
Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital
Global collaboration agreement with Genmab A/S
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
Locaweb Serviços de Internet S.A.
Advised Locaweb, a pioneer in B2B tech solutions for businesses digital transformation in Brazil with 2 main pillars: BeOnline/SaaS and Commerce
Infracommerce
Advised Brazil-based Infracommerce, a leader in designing, building and delivering the digital B2C and B2B go-to-market strategy for large enterprises, on its Series E funding round
Sye business area of Net Insight AB
Advised Net Insight AB, a global leader in media networks, on the sale of Sye, a market-leading true live “over-the-top” (OTT) technology for low-latency live streaming, to Amazon.com, Inc.
Portal de Documentos
Advised Portal de Documentos, a provider of digital solutions for participants in the credit cycle, with procedures for credit collection, renegotiation and servicing of vehicle and real estate loans, on its 100% sale to Brazil’s Stock Exchange, B3 S.A. – Brasil, Bolsa, Balcão
Blu Pagamentos
Advised Blu Pagamentos, a high-growth Brazilian B2B cash management fintech firm, on the sale of a minority stake
US$115mm Debt Facility from SQM
Advised Kidman Resources Limited, an ASX-listed hard rock lithium mining company with a 50% interest in the West Australian Mt. Holland lithium project, on a US$115mm debt facility provided by JV partner Sociedad Quimica y Minera de Chile S.A. (SQM), a leading global lithium producer
Cura Imagem e Diagnóstico Ltda.
Advised Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners
Cura Imagem e Diagnóstico Ltda.
Advising Cura, a leading independent provider of diagnostic imaging (MRI, CT, etc.) and other clinical analysis services on the sale of 70% of its stake to the PE fund Vinci Partners
Lonmin
Advising Lonmin PLC, a major fully integrated producer of Platinum Group Metals, on the amendment of its debt facilities to support the review and implementation of its strategic options
Radiogroup Participações S.A.
Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas
Rico
Advised the founding shareholders of Rico, a leading independent online investment platform in Brazil, on its 100% sale to XP Investimentos, a Brazilian investment firm
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories